Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
Amgen
Meletios Dimopoulos; Hang Quach; Maria-Victoria Mateos; Ola Landgren; Xavier Leleu; David Siegel; Katja Weisel; Hui Yang; Zandra Klippel; Anita Zahlten-Kumeli; Saad Z Usmani